In a phase II study of idarubicin (12 mg/m2/day × 3) and high dose cytarabine (1.5 g/m2/day × 4) plus escalating doses of crenolanib (60–100 mg three times a day) in relapsed/refractory AML patients with FLT3 mutations [40], four of the six patients who had failed ≤2 lines of therapy attained CR of their disease. The gene discussed is FLT3; the disease is acute myeloid leukemia.